MAP2K7 and ovarian carcinoma: In a phase I clinical study of a rare ovarian cancer subtype, Spreafico reported that favorable objective responses were obtained by simultaneous inhibition of MEK and PI3K in patients with KRAS mutation-associated ovarian cancer [87].